glp 1 compound ending 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these GLP-1 weight loss drugs are

In Phase II trials: Efinopegdutide (Merck/Johnson & Johnson/Hanmi Harma), VK2735 (Viking Therapeutics), BGM0504 (BrightGene), Pemvidutide (Altimmune/Spitfire Pharma), AMG133 (Amgen), Dapiglutide (Zealand Pharma), etc

That will prevent most compounding pharmacies from making and selling cheaper versions of the drug within the next few months

Restrain/Challenge Lack of Standardization and Clear Definition of GLP-1 Friendly Products The primary barrier to the growth of the GLP-1 friendly packaged food & beverage market is the lack of a defined concept of what constitutes "GLP-1 friendly." The phrase lacks a universal definition and has a lot of marketing behind it

According to SURPASS-2 clinical trials, it has shown to be very effective in treating type 2 diabetes, especially compared to other drugs on the market, such as semaglutide

These medications, including Semaglutide GLP-1 and Tirzepatide , are prescribed for weight management and are prescribed based on individual health assessments